Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Options Exercise Instructions
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

Lynx Financial Appointed as Corporate Advisor to Advance Commercialisation Strategy in China

9 June 2017 by Audrey Thomson

Lynx Financial Appointed as Corporate Advisor to Advance Commercialisation Strategy in China

Categories 2017, ASX Announcements
Post navigation
Rights Issue Prospectus
Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 24 February 2021        Legal Notices and Privacy